Novo Nordisk Expands Rare Disease Pipeline with US$2.4 B Omeros Partnership
By Hitesh Udar
Pharma Deals Review: Vol 2025 Issue 10 (Table of Contents)
Published: 31 Oct-2025
DOI: 10.3833/pdr.v2025.i10.2979 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Making a move into complement-mediated rare diseases, Novo Nordisk has entered into a definitive asset purchase and licensing agreement with Omeros for its clinical stage MASP-3-inhibitor humanised monoclonal antibody, zaltenibart (OMS906)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS